These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23895653)

  • 1. Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma.
    Hassler MR; Schiefer AI; Egger G
    Epigenomics; 2013 Aug; 5(4):397-415. PubMed ID: 23895653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?
    Lue JK; Amengual JE; O'Connor OA
    Curr Oncol Rep; 2015 Sep; 17(9):40. PubMed ID: 26141799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
    Apuri S; Sokol L
    Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the cancer epigenome for therapy.
    Jones PA; Issa JP; Baylin S
    Nat Rev Genet; 2016 Sep; 17(10):630-41. PubMed ID: 27629931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.
    Shi H; Guo J; Duff DJ; Rahmatpanah F; Chitima-Matsiga R; Al-Kuhlani M; Taylor KH; Sjahputera O; Andreski M; Wooldridge JE; Caldwell CW
    Carcinogenesis; 2007 Jan; 28(1):60-70. PubMed ID: 16774933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic targets in B- and T-cell lymphomas: latest developments.
    Ribeiro ML; Sánchez Vinces S; Mondragon L; Roué G
    Ther Adv Hematol; 2023; 14():20406207231173485. PubMed ID: 37273421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Hodgkin's lymphoma: the old and the new.
    Cabanillas F
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies.
    Zain J; O'Connor OA
    Invest New Drugs; 2010 Dec; 28 Suppl 1(Suppl 1):S58-78. PubMed ID: 21132350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation.
    Seitz V; Thomas PE; Zimmermann K; Paul U; Ehlers A; Joosten M; Dimitrova L; Lenze D; Sommerfeld A; Oker E; Leser U; Stein H; Hummel M
    Haematologica; 2011 Jun; 96(6):863-70. PubMed ID: 21393330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapy of non-Hodgkin's lymphomas. Introduction and overview.
    Vose JM; Bierman PJ; Weisenburger DD; Armitage JO
    Hematol Oncol Clin North Am; 1991 Oct; 5(5):845-52. PubMed ID: 1938757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus is infrequently identified in non-Hodgkin's lymphomas associated with Hodgkin's disease.
    Kingma DW; Medeiros LJ; Barletta J; Raffeld M; Mann RB; Ambinder RF; Jaffe ES
    Am J Surg Pathol; 1994 Jan; 18(1):48-61. PubMed ID: 8279628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Therapeutics: A New Weapon in the War Against Cancer.
    Ahuja N; Sharma AR; Baylin SB
    Annu Rev Med; 2016; 67():73-89. PubMed ID: 26768237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New trends in non-Hodgkin's lymphoma therapy].
    Mazur G; Wróbel T; Jurczak W; Butrym A
    Postepy Hig Med Dosw (Online); 2006; 60():707-21. PubMed ID: 17245320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale behind using valproic acid for Non-Hodgkin lymphoma: a biomolecular perspective.
    Ridwansyah H; Wijaya I; Bashari MH; Kartamihardja AHS; Hernowo BS
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7486-7500. PubMed ID: 34919251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
    Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
    Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.
    Falahi F; van Kruchten M; Martinet N; Hospers GA; Rots MG
    Breast Cancer Res; 2014 Jul; 16(4):412. PubMed ID: 25410383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetics and cancer treatment.
    Kristensen LS; Nielsen HM; Hansen LL
    Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA demethylating agents and epigenetic therapy of cancer.
    Mani S; Herceg Z
    Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent Progress of Molecular Genetic Characteristics and Prognosis of Non-Hodgkin's Lymphoma--Review].
    Wang ZH; Xu M; Gu XL; Xu Z; Yu FY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):301-305. PubMed ID: 30738488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.